adherium

ASX Release

Adherium enters into additional $1 million short-term loan facility

Melbourne, Australia – 18 August 2026: Adherium Limited (ASX:ADR) ("Adherium" or "the Company"), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® has entered into additional funding of AUD$1 million via a short-term unsecured loan funding facility ("Loan Facility") from its major shareholder, Trudell Medical Limited ("Trudell"), a global leader in aerosol drug delivery and lung health devices from the management of respiratory conditions. The Loan Facility will provide funding for working capital requirements.

The Loan Facility is separate from the USD$1.65 million short-term unsecured loan facility provided by Trudell announced by the Company on 29 June 2026.

Details of Loan Facility

The material terms of the Loan Facility are:

Loan facility	The principal amount is AUD$1 million.
Drawdowns on Loan	Adherium may draw advances under the Loan Facility as required.
Interest	Interest will be charged on the principal amount at 12% per annum with interest capitalised monthly until repayment.
Repayment	The loan repayment date is 30 September 2026 unless Trudell and Adherium mutually agree to extend the repayment date on a month to month basis. Adherium may repay the Loan Facility at any time prior to the repayment date without penalty. The Loan Facility will become immediately repayable where there is an event of default.
Security	The Loan Facility is unsecured.

Consideration of the Board

The Company has chosen to obtain the Loan Facility from Trudell, rather than from an unrelated party, because alternative funding options (such as from third-party financiers), are limited, uncertain, or available only on terms that are materially less favourable to the Company on the basis that:

- the Loan Facility does not dilute existing shareholders;
- the interest rate is considered to be reasonable in the circumstances;
- the ability to quickly execute the Loan Facility as opposed to alternative funding options; and
- the funding available from Trudell is able to meet immediate working capital requirements.

The Board (with Mr George Baran who is associated with Trudell, abstaining) considers that the terms of the Loan Facility have been negotiated on arm's length terms, being on comparable terms to similar short term loans with unrelated parties, and therefore does not require shareholder approval under Part 2.E of the *Corporations Act 2001* (Cth).

Learn more at **adherium.com**

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries
Adherium Limited
investors@adherium.com

Media Enquiries:
Haley Chartres
H^CK Director
haley@hck.digital

About Adherium (ASX: ADR):
Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at **adherium.com**